Volume 12 Issue 3
May  2021
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2021  >  12(3): 324-328
Lin Yuejun, Zheng Bowen, Wu Tao, et al. Preliminary study of early diagnosis by contrast-enhanced ultrasound combined with mesenchymal stem cell therapy in improving prognosis of biliary ischemia after liver transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 324-328. doi: 10.3969/j.issn.1674-7445.2021.03.011
Citation: Lin Yuejun, Zheng Bowen, Wu Tao, et al. Preliminary study of early diagnosis by contrast-enhanced ultrasound combined with mesenchymal stem cell therapy in improving prognosis of biliary ischemia after liver transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 324-328. doi: 10.3969/j.issn.1674-7445.2021.03.011
shu

Preliminary study of early diagnosis by contrast-enhanced ultrasound combined with mesenchymal stem cell therapy in improving prognosis of biliary ischemia after liver transplantation

doi: 10.3969/j.issn.1674-7445.2021.03.011

  • Department of Ultrasound, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information
  • Corresponding author: Ren Jie, Email: renj@mail.sysu.edu.cn
  • Received Date: 2021-01-11
    Available Online: 2021-05-19
  • Publish Date: 2021-05-15
    Abstract
  •   Objective  To evaluate the clinical efficacy of early diagnosis by contrast-enhanced ultrasound (CEUS) combined with mesenchymal stem cell (MSC) therapy in the treatment of biliary ischemia after liver transplantation.  Methods  Clinical data of 9 recipients presenting with biliary ischemia detected by CEUS within 4 weeks after liver transplantation and diagnosed with non-anastomotic biliary stricture (NAS) within postoperative 1 year were retrospectively analyzed. In the conventional treatment group, 4 recipients were treated with conventional treatment including liver protection, cholagogic therapy and interventional therapy. In MSC treatment group, 5 recipients received intravenous infusion of MSC at 1, 2, 4, 8, 12 and 16 weeks after biliary ischemia detected by CEUS on the basis of conventional therapy. The interventional treatment and clinical prognosis within 1 year after liver transplantation were analyzed between two groups.  Results  Two recipients in the MSC treatment group required interventional therapy, which was initially given at 7-9 months after liver transplantation for 1-2 times. All recipients in the conventional treatment group required interventional therapy, which was initially delivered at postoperative 1-3 months for 2-6 times, earlier than that in the MSC treatment group. Within 1 year following liver transplantation, diffuse bile duct injury occurred in 2 recipients in MSC treatment group, and no graft dysfunction was observed. In the conventional treatment group, all recipients developed diffuse bile duct injury, and 2 recipients presented with graft dysfunction.  Conclusions  Early diagnosis of biliary ischemia after liver transplantation by CEUS combined with MSC therapy may delay and reduce the requirement of interventional therapy for NAS, and also improve clinical prognosis of the recipients.

     

    • FullText(HTML)
  • loading
    • References(27)
  • [1]
    BOEVA I, KARAGYOZOV PI, TISHKOV I. Post-liver transplant biliary complications: current knowledge and therapeutic advances[J]. World J Hepatol, 2021, 13(1): 66-79. DOI: 10.4254/wjh.v13.i1.66.
    [2]
    MAGRO B, TACELLI M, MAZZOLA A, et al. Biliary complications after liver transplantation: current perspectives and future strategies[J]. Hepatobiliary Surg Nutr, 2021, 10(1): 76-92. DOI: 10.21037/hbsn.2019.09.01.
    [3]
    KEANE MG, DEVLIN J, HARRISON P, et al. Diagnosis and management of benign biliary strictures post liver transplantation in adults[J]. Transplant Rev (Orlando), 2021, 35(1): 100593. DOI: 10.1016/j.trre.2020.100593.
    [4]
    KOHLI DR, DESAI MV, KENNEDY KF, et al. Patients with post-transplant biliary strictures have significantly higher rates of liver transplant failure and rejection: a nationwide inpatient analysis[J]. J Gastroenterol Hepatol, 2020, DOI: 10.1111/jgh.15388[Epubahead of print].
    [5]
    SHARMA S, GURAKAR A, JABBOUR N. Biliary strictures following liver transplantation: past, present and preventive strategies[J]. Liver Transpl, 2008, 14(6): 759-769. DOI: 10.1002/lt.21509.
    [6]
    VERDONK RC, BUIS CI, VAN DER JAGT EJ, et al. Nonanastomotic biliary strictures after liver transplantation, part 2: management, outcome, and risk factors for disease progression[J]. Liver Transpl, 2007, 13(5): 725-732. DOI: 10.1002/lt.21165.
    [7]
    OP DEN DRIES S, WESTERKAMP AC, KARIMIAN N, et al. Injury to peribiliary glands and vascular plexus before liver transplantation predicts formation of non-anastomotic biliary strictures[J]. J Hepatol, 2014, 60(6): 1172-1179. DOI: 10.1016/j.jhep.2014.02.010.
    [8]
    FRANCHITTO A, OVERI D, MANCINELLI R, et al. Peribiliary gland damage due to liver transplantation involves peribiliary vascular plexus and vascular endothelial growth factor[J]. Eur J Histochem, 2019, 63(2): 3022. DOI: 10.4081/ejh.2019.3022.
    [9]
    REN J, LU MD, ZHENG RQ, et al. Evaluation of the microcirculatory disturbance of biliary ischemia after liver transplantation with contrast-enhanced ultrasound: preliminary experience[J]. Liver Transpl, 2009, 15(12): 1703-1708. DOI: 10.1002/lt.21910.
    [10]
    ZHANG YC, LIU W, FU BS, et al. Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation[J]. Cytotherapy, 2017, 19(2): 194-199. DOI: 10.1016/j.jcyt.2016.11.005.
    [11]
    ABDELRAZIK H, GIORDANO E, BARBANTI BRODANO G, et al. Substantial overview on mesenchymal stem cell biological and physical properties as an opportunity in translational medicine[J]. Int J Mol Sci, 2019, 20(21): 5386. DOI: 10.3390/ijms20215386.
    [12]
    CHOI JR, YONG KW, NAM HY. Current status and perspectives of human mesenchymal stem cell therapy[J]. Stem Cells Int, 2019: 4762634. DOI: 10.1155/2019/4762634.
    [13]
    MAEDA S, MIYAGAWA S, KAWAMURA T, et al. Notch signaling-modified mesenchymal stem cells improve tissue perfusion by induction of arteriogenesis in a rat hindlimb ischemia model[J]. Sci Rep, 2021, 11(1): 2543. DOI: 10.1038/s41598-021-82284-3.
    [14]
    张英才, 姚嘉, 邓宜南, 等. 联合间充质干细胞简化方案在ABO血型不符肝移植患者中的应用[J/CD]. 中华肝脏外科手术学电子杂志, 2016, 5(6): 380-384. DOI: 10.3877/cma.j.issn.2095-3232.2016.06.009.

    ZHANG YC, YAO J, DENG YN, et al. Application of simplified protocol combining with mesenchymal stem cell in ABO-incompatible liver transplant patients[J/CD]. Chin J Hepatic Surg (Electr Edit), 2016, 5(6): 380-384. DOI: 10.3877/cma.j.issn.2095-3232.2016.06.009.
    [15]
    任杰, 吕艳, 廖梅, 等. 超声造影定性诊断肝移植缺血性胆道病变及评估预后的临床研究[J]. 中华超声影像学杂志, 2013, 22(9): 784-787. DOI:10.3760/cma.j.issn. 1004-4477.2013.09.014.

    REN J, LYU Y, LIAO M, et al. Clinical study on diagnosis and prognosis assessment of ischemic-type biliary lesion in liver transplantation by contrast-enhanced ultrasound[J]. Chin J Ultrason, 2013, 22(9): 784-787. DOI: 10.3760/cma.j.issn.1004-4477.2013.09.014.
    [16]
    DENG Y, YI S, WANG G, et al. Umbilical cord-derived mesenchymal stem cells instruct dendritic cells to acquire tolerogenic phenotypes through the IL-6-mediated upregulation of SOCS1[J]. Stem Cells Dev, 2014, 23(17): 2080-2092. DOI: 10.1089/scd.2013.0559.
    [17]
    DE VRIES Y, VON MEIJENFELDT FA, PORTE RJ. Post-transplant cholangiopathy: classification, pathogenesis, and preventive strategies[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B): 1507-1515. DOI: 10.1016/j.bbadis.2017.06.013.
    [18]
    蔡晓波, 朱峰, 翁坚军, 等. 肝移植术后胆管吻合口狭窄和非吻合口狭窄内镜治疗的比较[J]. 中华消化内镜杂志, 2012, 29(7): 389-392. DOI: 10.3760/cma.j.issn. 1007-5232.2012.07.008.

    CAI XB, ZHU F, WENG JJ, et al. Therapeutic effect of endoscopy for anastomotic and nonanastomotic biliary strictures after liver transplantation[J]. Chin J Dig Endosc, 2012, 29(7): 389-392. DOI: 10.3760/cma.j.issn.1007-5232.2012.07.008.
    [19]
    汪邵平, 郑于剑, 李鹏, 等. 肝移植术后胆道非吻合口狭窄的诊治[J]. 中华肝胆外科杂志, 2014, 20(8): 577-581. DOI: 10.3760/cma.j.issn.1007-8118.2014.08.007.

    WANG SP, ZHENG YJ, LI P, et al. Diagnosis and management of non-anastomotic biliary stricture after liver transplantation[J]. Chin J Hepatobiliary Surg, 2014, 20(8): 577-581. DOI: 10.3760/cma.j.issn.1007-8118. 2014.08.007.
    [20]
    VILLA NA, HARRISON ME. Management of biliary strictures after liver transplantation[J]. Gastroenterol Hepatol (N Y), 2015, 11(5): 316-328.
    [21]
    BORTOLASI L, VIOLI P, CARRARO A, et al. Complications and outcomes of endoscopic treatment in a cohort of patients with biliary stenosis after orthotopic liver transplant: a retrospective observational study[J]. Exp Clin Transplant, 2019, 17(4): 513-521. DOI: 10.6002/ect.2018.0167.
    [22]
    GRAZIADEI IW, SCHWAIGHOFER H, KOCH R, et al. Long-term outcome of endoscopic treatment of biliary strictures after liver transplantation[J]. Liver Transpl, 2006, 12(5): 718-725. DOI: 10.1002/lt.20644.
    [23]
    BARBARO F, TRINGALI A, LARGHI A, et al. Endoscopic management of non-anastomotic biliary strictures following liver transplantation: long-term results from a single-center experience[J]. Dig Endosc, 2020, DOI: 10.1111/den.13879[Epubahead of print].
    [24]
    HANSEN T, HOLLEMANN D, PITTON MB, et al. Histological examination and evaluation of donor bile ducts received during orthotopic liver transplantation--a morphological clue to ischemic-type biliary lesion?[J]. Virchows Arch, 2012, 461(1): 41-48. DOI: 10.1007/s00428-012-1245-8.
    [25]
    BRUNNER SM, JUNGER H, RUEMMELE P, et al. Bile duct damage after cold storage of deceased donor livers predicts biliary complications after liver transplantation[J]. J Hepatol, 2013, 58(6): 1133-1139. DOI: 10.1016/j.jhep.2012.12.022.
    [26]
    MALHOTRA P, SHUKLA M, MEENA P, et al. Mesenchymal stem cells are prospective novel off-the-shelf wound management tools[J]. Drug Deliv Transl Res, 2021, DOI: 10.1007/s13346-021-00925-6[Epubahead of print].
    [27]
    MICELI V, BULATI M, IANNOLO G, et al. Therapeutic properties of mesenchymal stromal/stem cells: the need of cell priming for cell-free therapies in regenerative medicine[J]. Int J Mol Sci, 2021, 22(2): 763. DOI: 10.3390/ijms22020763.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (313) PDF downloads(44) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return